What is SpliSense?
Based in Jerusalem, Israel, SpliSense is a biopharmaceutical company established in 2016. The company is dedicated to developing groundbreaking mRNA-altering treatments designed to address critical unmet needs within genetic pulmonary diseases. SpliSense's focus on this specialized area positions it within the rapidly evolving landscape of genetic medicine, aiming to bring novel therapeutic solutions to patients suffering from debilitating conditions.
How much funding has SpliSense raised?
SpliSense has raised a total of $41.5M across 2 funding rounds:
Series B
$28.5M
Other Financing Round
$13M
Series B (2021): $28.5M with participation from Cystic Fibrosis Foundation, Integra Holdings, Israel Biotech Fund, Biotel Limited, and OrbiMed
Other Financing Round (2026): $13M led by Cystic Fibrosis Foundation
Key Investors in SpliSense
Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation, headquartered in Bethesda, Maryland, is a non-profit organization dedicated to finding a cure for cystic fibrosis and improving the lives of those affected by the disease. Their investment in SpliSense highlights a strategic focus on advancing treatments for genetic pulmonary conditions.
Integra Holdings
Integra Holdings acts as an investment gateway for early-stage life science research from Hebrew University, focusing on translating academic innovations into successful ventures, particularly in biotech and AI. Their participation suggests an interest in SpliSense's novel mRNA technology.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health. Their investment in SpliSense indicates a strategic alignment with innovative biopharmaceutical companies developing advanced therapeutic solutions.
What's next for SpliSense?
The substantial enterprise-level backing SpliSense has garnered, particularly the recent strategic investment, signals a strong vote of confidence from its investors. This financing is expected to fuel the company's research and development efforts, potentially accelerating clinical trials and expanding its therapeutic portfolio. The company's trajectory, marked by consistent capital infusions, indicates a strategic push towards commercialization and broader market penetration for its innovative mRNA-based therapies.
See full SpliSense company page
